Intranasal Administration of Genetically Modified Lactococcus Lactis Producing PD-L1 scFv Improves Survival in Lung Cancer Model Mice

被引：0
|
作者：
Nomura, N. [1 ]
Namai, F. [1 ]
Sato, T. [1 ]
Shimosato, T. [1 ]
机构：
[1] Shinshu Univ, Inst Biomed Sci, Nagano, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5754
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer
    Zeng, Liang
    Zhou, Yuling
    Xu, Qinqin
    Huang, Zhe
    Song, Lianxi
    Wang, Zhan
    Deng, Li
    Wu, Yongsheng
    Liang, Yanchao
    Liu, Zhentian
    Gao, Xuan
    Yi, Xin
    He, Qiongzhi
    Xia, Xuefeng
    Yang, Haiyan
    Zhang, Xing
    Yan, Huan
    Qin, Haoyue
    Lin, Shaoding
    Yang, Nong
    Zhang, Yongchang
    LUNG CANCER, 2023, 184
  • [32] Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model
    Lan, Hongwei
    Zhu, Jingjuan
    Hou, Helei
    Zhang, Chuantao
    Huo, Xingfa
    Zhang, Yuming
    Yang, Fangfang
    Zhou, Na
    Zhang, Xiaochun
    CELL COMMUNICATION AND SIGNALING, 2025, 23 (01)
  • [33] Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
    Huang, Qingyuan
    Zhang, Hua
    Hai, Josephine
    Socinski, Mark A.
    Lim, Eric
    Chen, Haiquan
    Stebbing, Justin
    ONCOIMMUNOLOGY, 2018, 7 (12):
  • [34] Soluble PD-L1 shows no association to relapse and overall survival in stage non-small cell lung cancer (NSCLC)
    Mildner, F. O.
    Sykora, M. M.
    Hackl, H.
    Amann, A.
    Zelger, B.
    Sprung, S.
    Buch, M. L.
    Nocera, F.
    Moser, P.
    Maier, H.
    Augustin, F.
    Manzl, C.
    Kocher, F.
    Pircher, A.
    Lindenmann, J.
    Mykoliuk, I
    Raftopoulou, S.
    Kargl, J.
    Wolf, D.
    Sopper, S.
    Gamerith, G.
    LUNG CANCER, 2024, 196
  • [35] PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC)
    Nesline, Mary K.
    Pabla, Sarabjot
    Lee, Yong Hee
    DePietro, Paul
    Early, Amy
    Klein, Roger
    Zhang, Shengle
    Conroy, Jeffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [36] PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis
    Zhou, Ze-Jun
    Zhan, Ping
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) : 203 - 208
  • [37] iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors
    Park, Wungki
    Florou, Vaia
    Algaze, Sandra
    Saravia, Diana
    Kwon, Deukwoo
    Lopes, Gilberto
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [38] Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab
    Xiao, Xuejun
    Wu, Yang
    Shen, Fang
    MuLaTiAize, Yusufu
    Xinhua, Nabi
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [39] Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab
    Xiao, Xuejun
    Wu, Yang
    Shen, Fang
    MuLaTiAize, Yusufu
    Xinhua, Nabi
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [40] Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Madala, S.
    Rasul, R.
    Singla, K.
    Sison, C. P.
    Seetharamu, N.
    Castellanos, M. R.
    CLINICAL ONCOLOGY, 2022, 34 (12) : 799 - 809
12345